The power of AI for Novonesis isn't the algorithm itself, but its application to a massive, well-structured proprietary dataset. Their organized library of 100,000 strains allows AI to rapidly predict protein shapes and accelerate R&D in ways competitors cannot match.

The 2012 breakthrough that ignited the modern AI era used the ImageNet dataset, a novel neural network, and only two NVIDIA gaming GPUs. This demonstrates that foundational progress can stem from clever architecture and the right data, not just massive initial compute power, a lesson often lost in today's scale-focused environment.

Professor Collins' AI models, trained only to kill a specific pathogen, unexpectedly identified compounds that were narrow-spectrum—sparing beneficial gut bacteria. This suggests the AI is implicitly learning structural features correlated with pathogen-specificity, a highly desirable but difficult-to-design property.

The next leap in biotech moves beyond applying AI to existing data. CZI pioneers a model where 'frontier biology' and 'frontier AI' are developed in tandem. Experiments are now designed specifically to generate novel data that will ground and improve future AI models, creating a virtuous feedback loop.

The future of valuable AI lies not in models trained on the abundant public internet, but in those built on scarce, proprietary data. For fields like robotics and biology, this data doesn't exist to be scraped; it must be actively created, making the data generation process itself the key competitive moat.

To overcome a small training set, researchers discretized continuous growth inhibition data into a binary (yes/no) classification. This simplified the learning task, enabling the model to achieve high predictive power where a more complex regression model would have failed due to insufficient data.

The most fundamental challenge in AI today is not scale or architecture, but the fact that models generalize dramatically worse than humans. Solving this sample efficiency and robustness problem is the true key to unlocking the next level of AI capabilities and real-world impact.

The AI-discovered antibiotic Halicin showed no evolved resistance in E. coli after 30 days. This is likely because it hits multiple protein targets simultaneously, a complex property that AI is well-suited to identify and which makes it exponentially harder for bacteria to develop resistance.

The groundbreaking AI-driven discovery of antibiotics is relatively unknown even within the AI community. This suggests a collective blind spot where the pursuit of AGI overshadows simpler, safer, and more immediate AI applications that can solve massive global problems today.